These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 17053872)

  • 1. Alois Alzheimer revisited: differences in origin of the disease carrying his name.
    Maurer K; Hoyer S
    J Neural Transm (Vienna); 2006 Nov; 113(11):1645-58. PubMed ID: 17053872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update.
    Hoyer S
    Exp Gerontol; 2000 Dec; 35(9-10):1363-72. PubMed ID: 11113614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta.
    Salkovic-Petrisic M; Osmanovic J; Grünblatt E; Riederer P; Hoyer S
    J Alzheimers Dis; 2009; 18(4):729-50. PubMed ID: 19661616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease.
    Hoyer S
    Eur J Pharmacol; 2004 Apr; 490(1-3):115-25. PubMed ID: 15094078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications.
    Hoyer S
    Adv Exp Med Biol; 2004; 541():135-52. PubMed ID: 14977212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for Alzheimer's disease during aging. Impacts of glucose/energy metabolism.
    Hoyer S
    J Neural Transm Suppl; 1998; 54():187-94. PubMed ID: 9850927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease.
    Hoyer S
    Acta Neurol Scand Suppl; 1996; 165():18-24. PubMed ID: 8740985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis.
    Graeber MB; Kösel S; Egensperger R; Banati RB; Müller U; Bise K; Hoff P; Möller HJ; Fujisawa K; Mehraein P
    Neurogenetics; 1997 May; 1(1):73-80. PubMed ID: 10735278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Models of Alzheimer's disease: cellular and molecular aspects.
    Hoyer S
    J Neural Transm Suppl; 1997; 49():11-21. PubMed ID: 9266410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alois Alzheimer (1864-1915) and the Alzheimer syndrome.
    Vishal S; Sourabh A; Harkirat S
    J Med Biogr; 2011 Feb; 19(1):32-3. PubMed ID: 21350079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer-type lesions in Huntington's disease.
    Jellinger KA
    J Neural Transm (Vienna); 1998; 105(8-9):787-99. PubMed ID: 9869319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormalities in brain glucose utilization and its impact on cellular and molecular mechanisms in sporadic dementia of Alzheimer type.
    Hoyer S
    Ann N Y Acad Sci; 1993 Sep; 695():77-80. PubMed ID: 8239317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer--certitudes and hypotheses.
    Amihăesei IC; Cojocarut E; Mungiu OC
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(1):119-26. PubMed ID: 24505903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The unsolved relationship of brain aging and late-onset Alzheimer disease.
    Kern A; Behl C
    Biochim Biophys Acta; 2009 Oct; 1790(10):1124-32. PubMed ID: 19632303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alzheimer's disease due to presenilin mutations].
    Tabira T
    Nihon Rinsho; 2004 Jan; 62 Suppl():90-4. PubMed ID: 15011327
    [No Abstract]   [Full Text] [Related]  

  • 16. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review.
    Hoyer S
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):991-1002. PubMed ID: 12111436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain.
    Riederer P; Hoyer S
    J Neural Transm (Vienna); 2006 Nov; 113(11):1671-7. PubMed ID: 17053873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GSK3: a possible link between beta amyloid peptide and tau protein.
    Hernández F; Gómez de Barreda E; Fuster-Matanzo A; Lucas JJ; Avila J
    Exp Neurol; 2010 Jun; 223(2):322-5. PubMed ID: 19782073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer culprits: cellular crossroads and interplay.
    Claeysen S; Cochet M; Donneger R; Dumuis A; Bockaert J; Giannoni P
    Cell Signal; 2012 Sep; 24(9):1831-40. PubMed ID: 22627093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.